We're still processing the latest earnings report of this company
Past criteria checks 0/6
Renascience has been growing earnings at an average annual rate of 25.4%, while the Pharmaceuticals industry saw earnings growing at 7.1% annually. Revenues have been declining at an average rate of 8.3% per year.
How Renascience makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
TSE:4889 Revenue, expenses and earnings (JPY Millions)
Date
Revenue
Earnings
G+A Expenses
R&D Expenses
31 Dec 25
107
-259
248
132
30 Sep 25
87
34
210
132
30 Jun 25
102
63
194
132
31 Mar 25
132
113
159
132
31 Dec 24
139
118
54
236
30 Sep 24
129
-235
124
236
30 Jun 24
141
-276
151
236
31 Mar 24
194
-258
167
236
31 Dec 23
190
-331
245
235
30 Sep 23
200
-277
201
235
30 Jun 23
173
-270
193
235
31 Mar 23
100
-335
185
235
31 Dec 22
103
-316
250
82
30 Sep 22
128
-288
245
82
30 Jun 22
128
-285
218
82
31 Mar 22
139
-254
193
82
31 Mar 21
209
-100
265
0
31 Mar 20
72
-184
235
0
Quality Earnings: 4889 is currently unprofitable.
Growing Profit Margin: 4889 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4889 is unprofitable, but has reduced losses over the past 5 years at a rate of 25.4% per year.
Accelerating Growth: Unable to compare 4889's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4889 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.3%).
Return on Equity
High ROE: 4889 has a negative Return on Equity (-10.72%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
7D
1Y
7D
1Y
7D
1Y
Company Analysis and Financial Data Status
Data
Last Updated (UTC time)
Company Analysis
2026/05/14 09:01
End of Day Share Price
2026/05/14 00:00
Earnings
2025/12/31
Annual Earnings
2025/03/31
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Renascience Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.